Equity Analysis /

AU : Medlab Clinical - Share consolidation

    Iain Wilkie
    Iain Wilkie

    Analyst - Healthcare & Biotechnology

    11 August 2022
    Published byCGS-CIMB

    In this note, we roll through the recent 150-for-1 consolidation of shares in MDC. We have made no other changes to our model at this stage. Our price target updates to A$44.53 and we retain our Speculative Buy recommendation.